{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T23:32:11Z","timestamp":1769211131033,"version":"3.49.0"},"reference-count":10,"publisher":"American Association for Cancer Research (AACR)","issue":"11","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Summary:<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T cells targeting mesothelin plus pembrolizumab, and atezolizumab plus bevacizumab, have recently shown clinical efficacy in phase I trials in malignant pleural and peritoneal mesothelioma. Despite being tested in a highly selected patient population and requiring a complex engineering that can hardly be upscaled, CAR T cells combined with pembrolizumab bring the first proof of efficacy in cold solid tumors with low genomic heterogeneity, while atezolizumab\u2013bevacizumab offers an easy-to-use combination of antiangiogenics and immunotherapy in an orphan disease.<\/jats:p>\n                  <jats:p>See related article by Raghav et al., p. 2738.<\/jats:p>\n                  <jats:p>See related article by Adusumilli et al., p. 2748.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-21-1046","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T08:35:17Z","timestamp":1635755717000},"page":"2674-2676","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["New Immunotherapy Combinations Enter the Battlefield of Malignant Mesothelioma"],"prefix":"10.1158","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7685-051X","authenticated-orcid":false,"given":"Mihaela","family":"Aldea","sequence":"first","affiliation":[{"name":"1School of Medicine, Paris-Saclay University, Paris, France."},{"name":"2Cancer Medicine Department, Gustave Roussy, Villejuif, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Carlos","family":"Benitez","sequence":"additional","affiliation":[{"name":"1School of Medicine, Paris-Saclay University, Paris, France."},{"name":"2Cancer Medicine Department, Gustave Roussy, Villejuif, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Chaput","sequence":"additional","affiliation":[{"name":"3Laboratory of Immunomonitoring in Oncology, Gustave Roussy, Villejuif, France."},{"name":"4School of Pharmacy, Paris-Saclay University, Chatenay-Malabry, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[{"name":"1School of Medicine, Paris-Saclay University, Paris, France."},{"name":"2Cancer Medicine Department, Gustave Roussy, Villejuif, France."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2021,11,1]]},"reference":[{"key":"2022060711045165400_bib1","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022060711045165400_bib2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"2022060711045165400_bib3","doi-asserted-by":"crossref","first-page":"537","DOI":"10.21037\/tlcr.2018.10.04","article-title":"Malignant peritoneal mesothelioma: a review","volume":"7","author":"Broeckx","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"2022060711045165400_bib4","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/jclinpath-2014-202465","article-title":"Comparison of genomic abnormality in malignant mesothelioma by the site of origin","volume":"67","author":"Takeda","year":"2014","journal-title":"J Clin Pathol"},{"key":"2022060711045165400_bib5","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1158\/2159-8290.CD-21-0331","article-title":"Efficacy, safety, and biomarker analysis of combined PD-L1 (atezolizumab) and VEGF (bevacizumab) blockade in advanced malignant peritoneal mesothelioma","volume":"11","author":"Raghav","year":"2021","journal-title":"Cancer Discov"},{"key":"2022060711045165400_bib6","doi-asserted-by":"crossref","first-page":"e2025109","DOI":"10.1001\/jamanetworkopen.2020.25109","article-title":"Prevalence of high tumor mutational burden and association with survival in patients with less common solid tumors","volume":"3","author":"Shao","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2022060711045165400_bib7","doi-asserted-by":"crossref","first-page":"e109760","DOI":"10.1371\/journal.pone.0109760","article-title":"Copy number loss of the interferon gene cluster in melanomas is linked to reduced T cell infiltrate and poor patient prognosis","volume":"9","author":"Linsley","year":"2014","journal-title":"PLoS One"},{"key":"2022060711045165400_bib8","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti\u2013PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov"},{"key":"2022060711045165400_bib9","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1158\/2159-8290.CD-20-1638","article-title":"Overcoming resistance to tumor-targeted and immune-targeted therapies","volume":"11","author":"Aldea","year":"2021","journal-title":"Cancer Discov"},{"key":"2022060711045165400_bib10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","article-title":"Mesothelin-targeted CARs: driving T cells to solid tumors","volume":"6","author":"Morello","year":"2016","journal-title":"Cancer Discov"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/11\/11\/2674\/3103338\/2674.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/11\/11\/2674\/3103338\/2674.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T11:07:25Z","timestamp":1654600045000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/11\/11\/2674\/666419\/New-Immunotherapy-Combinations-Enter-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":10,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11,1]]},"published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-21-1046","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,1]]}}}